You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

DUBLIN--(BUSINESS WIRE)--The "Spinal Cord Injury - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Spinal Cord Injury - Pipeline Insight, 2020," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Spinal Cord Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Treatment Treatments for Spinal Cord Injury includes surgery, medication and physical therapy. The primary aid or measures should be taken immediately to minimize the injury. Corticosteroid injections may help in spinal cord injuries. Research is going on to find new treatment therapy including prostheses and medications that may promote nerve cell regeneration or improve the function of the nerves after a spinal cord injury. Neural prostheses (artificial body parts) are a potential new treatment for spinal cord injuries. Regular rehabilitation and assistive devices can improve the quality of life. Spinal Cord Injury Emerging Drugs Chapters This segment of the Spinal Cord Injury report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Spinal Cord Injury Emerging Drugs Hepatocyte growth factor (KP-100IT) is a recombinant human HGF (rhHGF). It is under Phase III clinical development for acute spinal cord injury and amyotrophic lateral sclerosis (ALS). Hepatocyte growth factor (HGF) is considered as an intrinsic repair and regeneration factor for various tissues and organs. The therapy has been received an orphan drug designation by the Ministry of Health, Labor and Welfare as of September 12, 2019. ES135 is a recombinant human acidic fibroblast growth factor (rhFGF1) with 135 amino acids. ES135 promote neurite outgrowth. The sequence of ES135 has been patented in Taiwan, EU, China and the United States. ES135 is undergoing a multi-center, double blind, randomized, placebo control study as the pivotal Phase 3 clinical trial for spinal cord injury. Spinal Cord Injury: Therapeutic Assessment This segment of the report provides insights about the different Spinal Cord Injury drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Spinal Cord Injury There are approx. 40+ key companies which are developing the therapies for Spinal Cord Injury. The companies which have their Spinal Cord Injury drug candidates in the most advanced stage, i.e. phase III include, Kringle Pharma. Phases This report covers around 40+ products under different phases of clinical development like Spinal Cord Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Products have been categorized under various Molecule types such as The drugs have been categorized under various product types like Mono, Combination and Mono/Combination. Spinal Cord Injury: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spinal Cord Injury therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spinal Cord Injury drugs. Report Highlights Spinal Cord Injury Report Insights Spinal Cord Injury Report Assessment Key Questions Answered Current Treatment Scenario and Emerging Therapies: Key Players Key Products For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/lr5ba5

Answer: 2020 Spinal Cord Injury Pipeline Insights - ResearchAndMarkets.com